A landmark study demonstrates the superior predictive power of proteomics-based screening for diabetic complications. The newly developed protein model achieved 90.8% accuracy in predicting diabetic retinal neurodegeneration, compared to just 73.9% for the Hippisley conventional method—a 17-percentage-point improvement that could meaningfully impact clinical outcomes. Researchers identified 71 distinct blood proteins associated with early retinal nerve damage, enabling risk stratification years before symptoms emerge. The prospective cohort study tracked 1,492 individuals with type 2 diabetes for six years using advanced retinal imaging technology. These findings suggest that incorporating proteomic analysis into routine diabetes screening protocols could identify high-risk patients eligible for early interventional strategies, potentially preventing irreversible vision loss in millions of patients worldwide.
Was this article helpful?
